OR WAIT null SECS
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending April 9, 2022.
“These data suggest that vaccine responses are reduced but can be improved by sufficient vaccine/virus exposure,” investigators stated.
Jeff Peterson, MD, explains the importance of the recent FDA announcement granting priority review of the Supplemental Biologics License Application for concomitant use of pegloticase injection (KRYSTEXXA) plus methotrexate for patients with uncontrolled gout.
ACR20 response was significantly higher in patients receiving either deucravacitinib 6 mg daily or 12 mg daily when compared with placebo.
Findings provide an advanced look at the potential future role of obinutuzumab in the management of SLE.
Patients with rheumatoid arthritis are at greater risk of cardiovascular disease, but how much do you know about the use of statins in these patients to reduce their risk of cardiovascular morbidity and mortality? Test your knowledge with this quiz.